Divalproex extended release for bipolar depression and brain changes
About this title
Read the official source — NCT00186186Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.
Understand this study
What did researchers investigate?
Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 99 years. Other eligibility criteria applied.
- Listed locations
- StanfordSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 99 Years
- Official registry ID
- NCT00186186
- Official title
Show the full official title
Depakote ER in Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Stanford
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Stanford University, a university.
Did this study involve medication?
Yes. The study involved medication, including Depakote ER.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 99 years. Other eligibility criteria applied.
